<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04088305</url>
  </required_header>
  <id_info>
    <org_study_id>Y75505-03</org_study_id>
    <nct_id>NCT04088305</nct_id>
  </id_info>
  <brief_title>Vancomycin Dosage Strategy Based on a Trough Concentration Model</brief_title>
  <official_title>Clinical Evaluation of a Vancomycin Dosage Strategy Based on a Serum Trough Concentration Model in Elderly Patients With Severe Pneumonia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University Third Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University Third Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study design:

      Allocation: Randomized Endpoint classification: Efficacy study Masking: Open label Primary
      purpose: Treatment Primary endpoint: Incidence of reaching the target serum trough
      concentration Secondary endpoint: Clinical efficiency, Antibiotic use, acute kidney injury.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective randomized control trial. There are two groups, study group and control
      group. Patients of study group accepted vancomycin strategies decided by a serum trough
      concentration model, and patients of control group accepted vancomycin dosage decided by
      attending physician. The primary endpoint is the incidence of reaching the target serum
      trough concentration, the secondary endpoint are clinical efficiency, antibiotic use and side
      effects such as acute kidney injury, etc.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence of vancomycin therapeutic serum trough concentrations</measure>
    <time_frame>before the fifth vancomycin dosage</time_frame>
    <description>The proportion of patients with vancomycin serum trough concentrations reaching target concentrations (â‰¥15mg/L)will be compared between study group and control group</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical success rate</measure>
    <time_frame>Seven days after vancomycin withdrawal.</time_frame>
    <description>the proportion of patients with clinical success</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vancomycin doses</measure>
    <time_frame>At the end of vancomycin therapy, an average of 10 days.</time_frame>
    <description>Vancomycin daily doses and totally doses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of acute kidney injury</measure>
    <time_frame>At the end of vancomycin treatment, an average of 10 days.</time_frame>
    <description>The incidence of vancomycin-associated acute kidney injury</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">66</enrollment>
  <condition>Pneumonia, Staphylococcal</condition>
  <arm_group>
    <arm_group_label>Study group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients of study group will accept vancomycin strategies decided by a serum trough concentration model.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients of control group will accept vancomycin dosages decided by attending physician.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dose</intervention_name>
    <description>Dosage of Vancocin decided by a serum trough concentration, instead of decided by attending physician</description>
    <arm_group_label>Study group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with doubted or diagnosed Methicillin-resistant Staphylococcus aureus severe
             pneumonia, and need vancomycin treatment.

          -  Sixty years and older.

        Exclusion Criteria:

          -  younger than 60 years old

          -  Accepted blood purification therapy

          -  Pregnancy

          -  Positive HIV antibody titre

          -  Had known or suspected tuberculosis or other infections caused by fungi at baseline.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Qingtao Zhou, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University Third Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Meng Wang, Dr.</last_name>
    <phone>+86-10-82265562</phone>
    <email>bysywangmeng@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking University Third Hospita</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100191</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qingtao Zhou, MD</last_name>
      <phone>86-10-82265562</phone>
      <email>zhouqingtaobysy@sina.com</email>
    </contact>
    <investigator>
      <last_name>Qingtao Zhou, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>September 7, 2019</study_first_submitted>
  <study_first_submitted_qc>September 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 12, 2019</study_first_posted>
  <last_update_submitted>March 11, 2020</last_update_submitted>
  <last_update_submitted_qc>March 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University Third Hospital</investigator_affiliation>
    <investigator_full_name>Qingtao Zhou</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>pneumonia</keyword>
  <keyword>vancomycin</keyword>
  <keyword>trough concentration</keyword>
  <keyword>elderly patients</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia, Staphylococcal</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

